Cyril Gaultier, MD

BIOS Clinical Research

Disclosure(s): Gilead Sciences, Inc.: Advisor/Consultant; GSK: Advisor/Consultant; Merck: Advisor/Consultant; ViiV: Advisor/Consultant

Poster(s):

• (P-387) Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET